CXCL8 and neoplasm: Regarding biomarkers for monitoring disease progression, we would like to note that the interleukin-8 serum level directly correlates with tumor burden and that variations in interleukin-8 during treatment with PD-1/PD-L1 inhibitors are associated with clinical response [60].